Scholar Rock (SRRK)
Company Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis.
The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases.
Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Country | United States |
IPO Date | May 25, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 128 |
CEO | David L. Hallal |
Contact Details
Address: 301 Binney Street Cambridge, Massachusetts United States | |
Website | https://scholarrock.com |
Stock Details
Ticker Symbol | SRRK |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001727196 |
CUSIP Number | 80706P103 |
ISIN Number | US80706P1030 |
Employer ID | 82-3750435 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
David L. Hallal | Chief Executive Officer & Chairman of the Board |
Robert Keith Woods | Chief Operating Officer |
Vikas Sinha C.A., CPA, M.B.A. | Chief Financial Officer |
Caryn Parlavecchio | Chief Human Resources Officer |
Dr. Akshay K. Vaishnaw M.D., Ph.D. | President of R&D, Member of Scientific Advisory Board and Director |
Dr. Jing L. Marantz M.B.A., M.D., Ph.D. | Chief Medical Officer |
Erin Moore CPA | Interim Principal Financial & Accounting Officer |
Junlin Ho J.D. | General Counsel & Corporate Secretary |
Mo Qatanani Ph.D. | Chief Scientific Officer |
Rushmie Nofsinger | Vice President of Corporate Affairs & Investor Relations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 11, 2025 | 4 | Filing |
Jun 03, 2025 | 8-K | Current Report |
May 30, 2025 | 4 | Filing |
May 30, 2025 | 4 | Filing |
May 30, 2025 | 4 | Filing |
May 30, 2025 | 4 | Filing |
May 30, 2025 | 4 | Filing |
May 30, 2025 | 4 | Filing |
May 23, 2025 | 4 | Filing |
May 23, 2025 | 4 | Filing |